Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14965151 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL14964930 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL14965940 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL14964732 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL14964990 | 0.83 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL14965132 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL14965258 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL14965361 | 0.79 | POLB (0.62) | — | |
| SCHEMBL14965138 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2 | |
| SCHEMBL14965467 | 0.76 | POLB (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| CN-104011054-A | Thieno- and furo-pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LTD | 2014-08-27 | — | — | CN | disclosed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | SMN1; SMN2 3669/4885ALDH1A1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.